The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery
An Open Label, Multicenter, Randomized, Controlled Study to Evaluate Efficacy and Safety of PROCRIT in Subjects Undergoing Elective Major Abdominal and/or Pelvic Surgery
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Terminated
The study was stopped due to slow enrollment
Other terminated trials from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Follicular Lymphoma · Phase PHASE2 · Oct 2011
- Advanced or Refractory Leukemia · Phase PHASE1 · Sep 2011
- Mononeuropathies · Phase PHASE2 · Jul 2011
- Arthralgia · Phase PHASE2 · Jul 2011
- Interstitial Cystitis · Phase PHASE4 · Jun 2011
More terminations from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Listed as NCT00350519, this PHASE4 trial focuses on Hemostasis, Surgical and remains terminated or withdrawn. Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Ortho Biotech Clinical Affairs, L.L.C.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.